BioSpace News Archive

NeuroBo Pharmaceuticals, Inc. today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer.

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that VIGPODER ™ (vigabatrin) for oral solution, USP , a treatment for appropriate patients with infantile spasms (IS), is now available.

GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024 at 3:00 pm EST.

Avery Dennison Corporation will host its first quarter 2024 earnings conference call in a live webcast at 12:00 p.m. ET on Wednesday, April 24, 2024.